NeuroPace07.24.19
NeuroPace Inc., a Silicon Valley-based medical technology company, has appointed Michael Favet as chief executive officer. Frank Fischer, after 20 years serving as CEO, continues with NeuroPace as chairman of the Board of Directors.
Favet has served on the NeuroPace board since 2016, and has been the acting chief commercial officer since 2018. Favet has twenty years of experience in senior management positions at a variety of medical technology companies, including Advanced Cardiac Therapeutics, Sonitus Medical, Ventus Medical, Boston Scientific, and Guidant. Most recently, Favet was a managing director for KCK’s medtech group, part of a family fund investing in medical technologies.
“Frank is an inspiring pioneer who has brought NeuroPace’s life-changing technology to thousands of people with epilepsy. I’m thrilled to build upon what he has created and to lead NeuroPace during this exciting period of commercial growth,” said Favet. “I look forward to working with our exceptional team to expand access to the RNS System to many more patients and continuing development of the technology for new disease states.”
For more than 20 years, Fischer has worked to ensure that NeuroPace has met the highest possible standards on behalf of patients and health care providers, from initial conception through successful product commercialization. As chairman of the Board, he will continue work with the leadership team and external partners to continue advancing RNS therapy and improving access to care for individuals living with uncontrolled epilepsy.
“It has been a privilege and an honor to lead NeuroPace through the achievements of the last 20 years,” said Fischer. “I have tremendous confidence in Mike’s leadership as he takes NeuroPace into the next phase of growth, and I remain deeply committed to working with the NeuroPace team to bring this groundbreaking therapy to as many patients as possible.”
“We appreciate Frank’s commitment and far-reaching contributions to the success of NeuroPace over the years, and are grateful for his continued involvement with the company and the epilepsy community,” said Joe Lacob, NeuroPace board member. “This is an exciting time for NeuroPace, as demonstrated by its recent product launches, incredible clinical outcomes, and strong market adoption. Mike Favet is an outstanding leader who will help accelerate commercial growth and further the company’s mission of improving the lives of millions of individuals suffering from medically refractory epilepsy and other brain disorders.”
Favet has served on the NeuroPace board since 2016, and has been the acting chief commercial officer since 2018. Favet has twenty years of experience in senior management positions at a variety of medical technology companies, including Advanced Cardiac Therapeutics, Sonitus Medical, Ventus Medical, Boston Scientific, and Guidant. Most recently, Favet was a managing director for KCK’s medtech group, part of a family fund investing in medical technologies.
“Frank is an inspiring pioneer who has brought NeuroPace’s life-changing technology to thousands of people with epilepsy. I’m thrilled to build upon what he has created and to lead NeuroPace during this exciting period of commercial growth,” said Favet. “I look forward to working with our exceptional team to expand access to the RNS System to many more patients and continuing development of the technology for new disease states.”
For more than 20 years, Fischer has worked to ensure that NeuroPace has met the highest possible standards on behalf of patients and health care providers, from initial conception through successful product commercialization. As chairman of the Board, he will continue work with the leadership team and external partners to continue advancing RNS therapy and improving access to care for individuals living with uncontrolled epilepsy.
“It has been a privilege and an honor to lead NeuroPace through the achievements of the last 20 years,” said Fischer. “I have tremendous confidence in Mike’s leadership as he takes NeuroPace into the next phase of growth, and I remain deeply committed to working with the NeuroPace team to bring this groundbreaking therapy to as many patients as possible.”
“We appreciate Frank’s commitment and far-reaching contributions to the success of NeuroPace over the years, and are grateful for his continued involvement with the company and the epilepsy community,” said Joe Lacob, NeuroPace board member. “This is an exciting time for NeuroPace, as demonstrated by its recent product launches, incredible clinical outcomes, and strong market adoption. Mike Favet is an outstanding leader who will help accelerate commercial growth and further the company’s mission of improving the lives of millions of individuals suffering from medically refractory epilepsy and other brain disorders.”
